Stifel analyst Craig Jones raised the firm’s price target on Alignment Healthcare (ALHC) to $18 from $16 and keeps a Buy rating on the shares. Revenue continues to outperform on strong new member adds and changes in CMS star-rating calculation could drive 0.23 rating points in 2026/2027 with additional changes potentially driving 0.25 rating points in 2027/2028, the analyst tells investors.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ALHC:
- Alignment Healthcare price target raised to $9 from $8 at Barclays
- Alignment Healthcare: Strong Financial Performance and Promising Outlook Justify Buy Rating
- Alignment Healthcare Reports Strong Growth and Positive Outlook
- Alignment Healthcare reports Q4 EPS (16c), consensus (8c)
- Alignment Healthcare sees Q1 adjusted EBITDA $2M-$10M